The antimalarial pipeline - An update

International Journal of Medical Microbiology

Volumn 302, Issue 4-5, 2012, Pages 165-171

  Schrader, Florian C ^a   Barho, Marlene ^a   Steiner, Iljana ^a   Ortmann, Regina ^a   Schlitzer, Martin ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clinical studies; Drug development; Malaria; Malaria therapy; Plasmodium Falciparum

Indexed keywords

ALBITIAZOLIUM BROMIDE; ANTIMALARIAL AGENT; AQ 13; ARTEMISONE; ARTEROLANE; ARTESUNATE PLUS PYRONARIDINE; AZITHROMYCIN; DF 02; DIHYDROARTEMISININ PLUS PIPERAQUINE; DSM 265; FERROQUINE; FOSMIDOMYCIN; GENZ 668764; GNF 156; MK 4815; NAPHTHOQUINONE; SAR 116242; SEVUPARIN; TAFENOQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARGEMONE MEXICANA; CHINA; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; SHORT SURVEY;

AMINOQUINOLINES; ANIMALS; ANTIMALARIALS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 84866627031     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2012.07.009     Document Type: Short Survey

References (57)

1. Adjalley S.H., Johnston G.L., Li T., Eastman R.T., Ekland E.H., Eappen A.G., Richman A., Kim Lee Sim B., Lee M.C.S., Hoffman S.L., Fidock D.A. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. PNAS 2011, 108:E1214-E1223.
2. Avello Simoes Pires C. Investigation of antiplasmodial compounds from various plant extracts Thèse de doctorat. Univ. Genève. no. Sc. 2009, 4129.
3. Barker R.H., Urgaonkar S., Mazitschek R., Celatka C., Skerlj R., Cortese J.F., Tyndall E., Liu H., Cromwell M., Sidhu A.B., Guerrero-Bravo J.E., Crespo-Llado K.N., Serrano A.E., Lin J.W., Janse C.J., Khan S.M., Duraisingh M., Coleman B.I., Angulo-Barturen I., Jiménez-Díaz M.B., Magán N., Gomez V., Ferrer S., Martínez M.S., Wittlin S., Papastogiannidis P., O'Shea T., Klinger J.D., Bree M., Lee E., Levine M., Wiegand R.C., Munoz B., Wirth D., Clardy F., Bathurst J., Sybertz I.E. Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum. Antimicrob. Agents Chemother. 2011, 55:2612-2622.
4. Batty K.T., Salman S., Moore B.R., Benjamin J., Lee S.T., Page-Sharp M., Pitus N., Ilett K.F., Mueller I., Hombhanje F.W., Siba P., Davis T.M. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob. Agents Chemother. 2012, 56:2472-2484.
5. Benjamin J., Moore B., Lee S.T., Senn M., Griffin S., Lautu D., Salman S., Siba P., Mueller I., Davis T.M. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob. Agents Chemother. 2012, 56:2465-2471.
6. Bountogo M., Zoungrana A., Coulibaly B., Klose C., Mansmann U., Mockenhaupt F.P., Burhenne J., Mikus G., Walter-Sack I., Schirmer R.H., Sié A., Meissner P., Müller O. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop. Med. Int. Health. 2010, 15:713-717.
7. Bousejra-El Garah F., Stigliani J.-L., Coslédan F., Meunier B., Robert A. Docking studies of structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico binding affinity and in vitro antimalarial activity. Chemmedchem 2009, 4:1469-1479.
8. Cassera M.B., Hazleton K.Z., Merino E.F., Obaldia N., Ho M.C., Murkin A.S., DePinto R., Gutierrez J.A., Almo S.C., Evans G.B., Babu Y.S., Schramm V.L. Plasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal model. PLoS ONE 2011, 6:e26916.
9. Charman S.A., Arbe-Barnes S., Bathurst I.C., Brun R., Campbell M., Charman W.N., Chiu F.C.K., Chollet J., Craft J.C., Creek D.J., Dong Y., Matile H., Maurer M., Morizzi J., Nguyen T., Papastogiannidis P., Scheurer C., Shackleford D.M., Sriraghavan K., Stingelin L., Tang Y., Urwyler H., Wang X., White K.L., Wittlin S., Zhou L., Vennerstrom J.L. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. PNAS 2011, 108:4400-4405.
10. Coslédan F., Fraisse L., Pellet A., Guillou F., Mordmüller B., Kremsner P.G., Moreno A., Mazier D., Maffrand J.-P., Meunier B. Selection of a trioxaquine as an antimalarial drug candidate. PNAS 2008, 105:17579-17584.
11. Coteron J.M., Marco M., Esquivias J., Deng X., White K.L., White J., Koltun M., El Mazouni F., Kokkonda S., Katneni K., Bhamidipati R., Shackleford D.M., Angulo-Barturen I., Ferrer S., Jiménez-Díaz M.B., Gamo F.J., Goldsmith E.J., Charman W.N., Bathurst I., Floyd D., Matthews D., Burrows J.N., Rathod P.K., Charman S.A., Phillips M.A. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem. 2011, 54:5540-5561.
12. Coulibaly B., Zoungrana A., Mockenhaupt F.P., Schirmer R.H., Klose C., Mansmann U., Meissner P.E., Müller O. Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS ONE 2009, 4:e5318.
13. Delves M., Plouffe D., Scheurer C., Meister S., Wittlin S., Winzeler E.A., Sinden R.E., Leroy D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012, 9:e1001169.
14. Dondorp A.M., Yeung S., White L., Nguon C., Day N.P., Socheat D., von Seidlein L. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 2010, 8:272-280.
15. Dunne M.W., Singh N., Shukla M., Valecha N., Bhattacharyya P.C., Dev V., Patel K., Mohapatra M.K., Lakhani J., Benner R., Lele C., Patki K. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J. Infect. Dis. 2005, 191:1582-1588.
16. Dutta A.K., Stodghill S.P., Wyandt C.M. Physicochemical characterization of NPC 1161C, a novel antimalarial 8-aminoquinoline, in solution and solid state. AAPS PharmSciTech 2011, 12:177-191.
17. Eastman R.T., Dharia N.V., Winzeler E.A., Fidock D.A. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents Chemother. 2011, 55:3908-3916.
18. Gargano N., Cenci F., Basset Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop. Med. Int. Health 2011, 16:1463-1476.
19. Haynes R.K., Cheu K.W., Li K.Y., Tang M.M., Wong H.N., Chen M.J., Guo Z.F., Guo Z.H., Coghi P., Monti D. A partial convergence in action of methylene blue and artemisinins: antagonism with chloroquine, a reversal with verapamil, and an insight into the antimalarial activity of chloroquine. ChemMedChem 2011, 6:1603-1615.
20. ®): an overview of the progress. Pharmaceuticals 2010, 3:3581-3593.
21. Hombhanje F.W., Linge D., Saweri A., Kuanch C., Jones R., Toraso S., Jacobed G., Geita, Masta A., Kevau I., Hiawalyer G., Sapuri M. Artemisinin-naphthoquine combination (ARCO™) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malaria J. 2009, 8:196.
22. Iyer J.K., Milhous W.K., Cortese J.F., Kublin J.G., Plowe C.V. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001, 358:1066-1067.
23. Kurth F., Bélard S., Basra A., Ramharter M. Pyronaridine-artesunate combination therapy for the treatment of malaria. Curr. Opin. Infect. Dis. 2011, 24:564-569.
24. Le Roche K., Johnson J., Ahiboh H., Chung W., Prudhomme J., Plouffe D., Henson K., Zhou Y., Witola W., Yates J., Mamoun C., Winzeler E., Vial H. A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum. BMC Genomics 2008, 9:513.
25. Leary K.J., Riel M.A., Roy M.J., Cantilena L.R., Bi D., Brater D.C., van de Pol C., Pruett K., Kerr C., Veazey J.M., Beboso R., Ohrt C. A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200mg weekly versus placebo for 6 months in healthy volunteers. Am. J. Trop. Med. Hyg. 2009, 81:356-362.
26. Leitgeb A.M., Blomqvist K., Cho-Ngwa F., Samje M., Nde P., Titanji V., Wahlgren M. Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. Am. J. Trop. Med. Hyg. 2011, 84:390-396.
27. Marfurt J., Chalfein F., Prayoga P., Wabiser F., Kenangalem E., Piera K.A., Machunter B., Tjitra E., Anstey N.M., Price R.N. Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob. Agents Chemother. 2011, 55:4461-4464.
28. McChesney, J., Nanayakkara, N.P.D., Bartlett, M., Agar, A.L., 2000. 8-Aminoquinolines. US Patent No. US 6376511 B2.
29. Meister S., Plouffe D.M., Kuhen K.L., Bonamy G.M.C., Wu T., Barnes S.W., Bopp S.E., Borboa R., Bright A.T., Che J., Cohen S., Dharia N.V., Gagaring K., Gettayacamin M., Gordon P., Groessl T., Kato N., Lee M.C.S., McNamara C.W., Fidock D.A., Nagle A., Nam T-g., Richmond W., Roland J., Rottmann M., Zhou B., Froissard P., Glynne R.J., Mazier D., Sattabongkot J., Schultz P.G., Tuntland T., Walker J.R., Zhou Y., Chatterjee A., Diagana T.T., Winzeler E.A. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 2011, 334:1372-1377.
30. Mesia K., Tona L., Mampunza M.M., Cimanga K., Totté J., Pieters L., Vlietinck A. Antimalarial efficacy of a quantified extract of Nauclea pobeguinii stem bark in human adult volunteers with diagnosed uncomplicated falciparum malaria: part 1: a clinical phase IIA trial. Planta Med. 2012, 78:211-218.
31. Mombo-Ngoma G., Christian Supan C., Dal-Bianco M.P., Missinou M.A., Matsiegui P.-B., Salazar C.L.O., Issifou S., Ter-Minassian D., Ramharter M., Kombila M., Kremsner P.G., Lell B. Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection. Malaria J. 2011, 10(53).
32. Murray C.J.L., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., Fullman N., Naghavi M., Lozano R., Lopez A.D. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
33. Nagelschmitz J., Voith B., Wensing G., Roemer A., Fugmann B., Haynes R.K., Kotecka B.M., Rieckmann K.H., Edstein M.D. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother. 2008, 52:3085-3091.
34. Nasveld P.E., Edstein M.D., Reid M., Brennan L., Harris I.E., Kitchener S.J., Leggat P.A., Pickford P., Kerr C., Ohrt C., Prescott W. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob. Agents Chemother. 2010, 54:792-798. Tafenoquine Study Team.
35. O'Neill P.M., Amewu R.K., Nixon G.L., Bousejra ElGarah F., Mungthin M., Chadwick J., Shone A.E., Vivas L., Lander H., Barton V., Muangnoicharoen S., Bray P.G., Davies J., Park B.K., Wittlin S., Brun R., Preschel M., Zhang K., Ward S.A. Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA182) with superior properties to the semisynthetic artemisinins. Angew. Chem. Int. Ed. 2010, 49:5693-5697.
36. O'Neill P.M., Barton V.E., Ward S.A., Chadwick J. 4-Aminoquinolines: Chloroquine Amodiaquine and Next-Generation Analogues 2012, 19. Springer Basel AG, pp. 44.
37. O'Neill P.M., Park B.K., Shone A.E., Maggs J.L., Roberts P., Stocks P.A., Biagini G.A., Bray P.G., Gibbons P., Berry N., Winstanley P.A., Mukhtar A., Bonar-Law R., Hindley S., Bambal R.B., Davis C.B., Bates M., Hart T.K., Gresham S.L., Lawrence R.M., Brigandi R.A., Gomez-delas-Heras F.M., Gargallo D.V., Ward S.A. Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J. Med. Chem. 2009, 52:1408-1415.
38. Pascual A., Henry M., Briolant S., Charras S., Baret E., Amalvict R., Huyghues des Etages E., Feraud M., Rogier C., Bruno Pradines B. In Vitro activity of proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob. Agents Chemother. 2011, 55:2472-2474.
39. Powles M.A., Allocco J., Yeung L., Nare B., Liberator P., Schmatz D. MK-4815, a potential new oral agent for treatment of malaria. Antimicrob. Agents Chemother. 2012, 56:2414-2419.
40. Pradel G., Schlitzer M. Antibiotics in malaria therapy and their effect on the parasite apicoplast. Curr. Mol. Med. 2010, 10:335-349.
41. Rottmann M., McNamara C., Yeung B.K.S., Lee M.C.S., Zou B., Russell B., Seitz P., Plouffe D.M., Dharia N.V., Tan J., Cohen S.B., Spencer K.R., González-Páez G.E., Lakshminarayana S.B., Goh A., Suwanarusk R., Jegla T., Schmitt E.K., Beck H.-P., Brun R., Nosten F., Renia L., Dartois V., Keller T.H., Fidock D.A., Winzeler E.A., Diagana T.T. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010, 329:1175-1180.
42. Singh, C., Puri, S.K., 2000. US6316493B1.
43. Singh R.P., Sabarinath S., Gautam N., Gupta R.C., Singh S.K. Liquid chromatographic tandem mass spectrometric assay for quantification of 97/78 and its metabolite 97/63: a promising trioxane antimalarial in monkey plasma. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2009, 877:2074-2080.
44. Tekwani B.L., Walker L.A. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis. 2006, 19(6):623-631.
45. Tun T., Tint H.S., Lin K., Kyaw T.T., Myint M.K., Khaing W., Tun Z.W. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Trop. 2009, 111:275-278.
46. Valecha N., Martensson Looareesuwan.S., et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin. Infect. Dis. 2010, 51:684-691.
47. van Eijk A.M., Terlouw D.J. Azithromycin for Treating Uncomplicated Malaria 2011, Wiley, pp. 2.
48. Waknine-Grinberg J.H., Hunt N., Bentura-Marciano A., James A., McQuillan J., Chan H.-W., Chan W.-C., Barenholz Y., Haynes R.K., Golenser J. Artemisone effective against murine cerebral malaria. Malaria J. 2010, 9:227.
49. Wang J-y., Cao W-c., Shan C-q., Zhang M., Li G-f., Ding D-b., Shi Y-l., Wu B-a. Naphthoquine phosphate and its combination with artemisinine. Acta Trop. 2004, 89:375-381.
50. Weaver M., Han X., Francese G., Babu S., Ramos R., Beltz K., Han B., Shieh W., Baenziger M., Grueninger H., Marrast A.-C., Aliu P., Lefevre G., Praestgaard J., Li R., Tanner M., White N. Discovery of novel antimalarials through cell based medicinal chemistry optimization of HTS hits. Med. Chem. Symp. 2011, 1-28.
51. Wells T.N., Poll E.M. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discov. Med. 2010, 9:389-398.
52. Wiesner J., Reichenberg A., Heinrich S., Schlitzer M., Jomaa H. The plastid-like organelle of apicomplexan parasites as drug target. Curr. Pharm. Des. 2008, 14:855-871.
53. Willcox M. Improved traditional phytomedicines in current use for the clinical treatment of malaria. Planta Med. 2011, 77:662-671.
54. Willcox M.L., Graz B., Falquet J., Diakite C., Giani S., Diallo D. A reverse pharmacology approach for developing an anti-malarial phytomedicine. Malaria J. 2011, 10:8.
55. Wu T., Nagle A., Kuhen K., Gagaring K., Borboa R., Francek C., Chen Z., Plouffe D., Goh A., Lakshminarayana S.B., Wu J., Ang H.Q., Zeng P., Kang M.L., Tan W., Tan M., Ye N., Lin X., Caldwell C., Ek J., Skolnik S., Liu F., Wang J., Chang J., Li C., Hollenbeck T., Tuntland T., Isbell J., Fischli C., Brun R., Rottmann M., Dartois V., Keller T., Diagana T., Winzeler E., Glynne R., Tully D.C., Chatterjee A.K. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. Chem. 2011, 54:5116-5130.
56. Yeh E., DeRisi J.L. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLOS Biol. 2011, 9:e1001138.
57. Yuthavong, Y., Vilaivan, T., Kamchonwongpaisan, S., Tarnchompoo, B., Thongpanchang, C., Chitnumsub, C., Yuvaniyama, J., Matthews, D., Charman, W., Charman, S., Vivas, L., Katiyar, S.B., 2009. Antimalarial compounds with flexible side-chains. Publication number: US 2009/0099220 A1.